PD-1 inhibitor and chemotherapeutic agents

This page covers all PD-1 inhibitor and chemotherapeutic agents drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1.

Targets

PD-1

Phase 3 pipeline (1)

• Tislelizumab plus Carboplatin and Paclitaxel · RemeGen Co., Ltd. · Oncology
  Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division.